We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Marijuana Stocks A 'Buy' Amid U.S. Decriminalization Bill?
Read MoreHide Full Article
Marijuana stocks trading on U.S. exchanges have rallied sharply over the past week, following news that U.S. Senate Democrats are introducing a federal cannabis decriminalization bill before the August recess.
The bill – known as the Cannabis Administration & Opportunity Act (CAOA) – was initially drafted a bit over a year ago. Senate Majority Leader Chuck Schumer has repeatedly stated his intentions for pushing a version of the bill through the Senate, although it remains unclear that it’ll reach the required 60 votes needed to pass. It’s anticipated that most Republican senators will likely oppose the bill, while not all Democrats are in favor either.
If signed into law, it would remove marijuana from the Controlled Substances Act (CSA). But the bill would still allow states to set their own marijuana policies. It would also expunge past non-violent convictions related to cannabis.
Marijuana-Related Investments
One way to gain exposure to the industry while limiting overall risk is to invest in marijuana-related ETFs. The ETFMG Alternative Harvest ETF (MJ - Free Report) tracks the Prime Alternative Harvest Index, which is designed to measure the performance of companies within the cannabis ecosystem that benefit from global medicinal and recreational cannabis legalization initiatives.
MJ was the first U.S. ETF to target the global cannabis industry. While MJ has suffered substantial losses this year along with the market, bullish investors are now targeting the space amid potential U.S. legalization. The ETF just witnessed its highest daily volume since March, when it rallied over 32% from the monthly bottom.
One specific holding within the ETFMG Alternative Harvest ETF is also seeing a spike in buying pressure. This company is the largest holding within MJ and accounts for over 8% of the total ETF constituency. The company is a component of the Zacks Medical – Drugs industry, which currently ranks in the top 39% out of approximately 250 industry groups. Note the favorable characteristics for this group below:
Image Source: Zacks Investment Research
Let’s take a deeper look at this marijuana-based company.
Based in Canada, Cronos Group manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also engaged in the cultivation and manufacturing of cannabis and related products for medical and adult-use markets. CRON also exports dried cannabis and oils to Germany, Israel, and Australia.
A Zacks Rank #3 (Hold), CRON most recently reported a Q1 loss back in May of -$0.08/share, in line with consensus estimates. Sales of $25.03 million exceeded estimates by 7.56%. While the stock has had a rough go this year along with the rest of the industry, shares have risen over 26% from the June bottom.
Image Source: StockCharts
Revenues are expected to climb 61.9% in 2022 to $120.5 million. Potential domestic legalization would render that estimate conservative. Make sure to keep an eye on CRON as well as the marijuana industry in the coming days and weeks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Marijuana Stocks A 'Buy' Amid U.S. Decriminalization Bill?
Marijuana stocks trading on U.S. exchanges have rallied sharply over the past week, following news that U.S. Senate Democrats are introducing a federal cannabis decriminalization bill before the August recess.
The bill – known as the Cannabis Administration & Opportunity Act (CAOA) – was initially drafted a bit over a year ago. Senate Majority Leader Chuck Schumer has repeatedly stated his intentions for pushing a version of the bill through the Senate, although it remains unclear that it’ll reach the required 60 votes needed to pass. It’s anticipated that most Republican senators will likely oppose the bill, while not all Democrats are in favor either.
If signed into law, it would remove marijuana from the Controlled Substances Act (CSA). But the bill would still allow states to set their own marijuana policies. It would also expunge past non-violent convictions related to cannabis.
Marijuana-Related Investments
One way to gain exposure to the industry while limiting overall risk is to invest in marijuana-related ETFs. The ETFMG Alternative Harvest ETF (MJ - Free Report) tracks the Prime Alternative Harvest Index, which is designed to measure the performance of companies within the cannabis ecosystem that benefit from global medicinal and recreational cannabis legalization initiatives.
MJ was the first U.S. ETF to target the global cannabis industry. While MJ has suffered substantial losses this year along with the market, bullish investors are now targeting the space amid potential U.S. legalization. The ETF just witnessed its highest daily volume since March, when it rallied over 32% from the monthly bottom.
One specific holding within the ETFMG Alternative Harvest ETF is also seeing a spike in buying pressure. This company is the largest holding within MJ and accounts for over 8% of the total ETF constituency. The company is a component of the Zacks Medical – Drugs industry, which currently ranks in the top 39% out of approximately 250 industry groups. Note the favorable characteristics for this group below:
Image Source: Zacks Investment Research
Let’s take a deeper look at this marijuana-based company.
Cronos Group Inc. (CRON - Free Report)
Based in Canada, Cronos Group manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also engaged in the cultivation and manufacturing of cannabis and related products for medical and adult-use markets. CRON also exports dried cannabis and oils to Germany, Israel, and Australia.
A Zacks Rank #3 (Hold), CRON most recently reported a Q1 loss back in May of -$0.08/share, in line with consensus estimates. Sales of $25.03 million exceeded estimates by 7.56%. While the stock has had a rough go this year along with the rest of the industry, shares have risen over 26% from the June bottom.
Image Source: StockCharts
Revenues are expected to climb 61.9% in 2022 to $120.5 million. Potential domestic legalization would render that estimate conservative. Make sure to keep an eye on CRON as well as the marijuana industry in the coming days and weeks.